This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. [link] Drug developers require access to scientific information in…. The post Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average appeared first on DrugPatentWatch - Make Better Decisions.
Overview Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Healthcare systems are being put under significant pressure, at a time when many are already over-stretched, medical congresses are being cancelled and bans on non-essential travel and enforced home working are emerging.
Being the most accessible healthcare professionals in our society during the COVID-19 pandemic has its tolls on pharmacies and their staff. Even in countries on complete lockdown, grocery stores and pharmacies remain open.
Fluvoxamine drug interactions can be clinically significant in clinical practice. It is a major reason why this medication is not used very often. If you ever see it on a medication list of one of your patients, you must do a drug interaction screen. According to the package insert, fluvoxamine can inhibit CYP1A2, CYP2C9, CYP3A4, […]. The post Fluvoxamine Drug Interactions appeared first on Med Ed 101.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Overview In today’s digital world it is increasingly hard for pharmaceutical companies to successfully differentiate new brands based on their target product profile alone. Instead, the key factor now is often the quality of customer engagement, which more and more healthcare professionals (HCPs) appear to value. It’s enabled by a multichannel marketing (MCM) approach, but traditional MCM strategies require a much higher level of content than pharma is used to producing and approving – the answe
The world is a buzz with COVID-19 news and rightfully so. I want to cover hydroxychloroquine clinical pearls. This drug has been purported to have activity against coronavirus. Here’s a link to that research article. Uses of Hydroxychloroquine While it is classified as an antimalarial agent, the most common, long term use for hydroxychloroquine that […].
40
40
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The world is a buzz with COVID-19 news and rightfully so. I want to cover hydroxychloroquine clinical pearls. This drug has been purported to have activity against coronavirus. Here’s a link to that research article. Uses of Hydroxychloroquine While it is classified as an antimalarial agent, the most common, long term use for hydroxychloroquine that […].
I’m seeing this article all over the place recommending to avoid NSAIDs in patients who have an infection with the new COVID-19 coronavirus. My question is, where’s the evidence? The only thing I can find is that it was based upon is a scientific theory as well as data that NSAIDs may not be good […]. The post Avoid NSAIDs in COVID-19?
Hey all, thanks so much for supporting the blog as well as the podcast! I’m amazed at how many people come to pick up a few pearls or listen to the drug of the week. Because of your support, I like to give annual sweet deals on our content! Today is the day for our […]. The post One Time Only! 50% Off 2020 NAPLEX Content appeared first on Med Ed 101.
Many patients will take acetaminophen for their pain management. It is cheap, somewhat effective, and typically pretty safe at normal dosages. There are potential downsides when it comes to acetaminophen. Let me outline a couple of common mistakes with acetaminophen. #1 Common Mistakes with Acetaminophen – Multiple Sources Many elderly patients do understand that acetaminophen […].
Tapering benzodiazepines or any drug for that matter is a bit of an art. Sure we do have some evidence on these types of topics, but we can’t also schedule a taper schedule perfectly based upon a percentage of the dose. Dosage forms and the patients themselves can throw a wrinkle into what we might […]. The post Tapering Benzodiazepines – Tricks of the Trade appeared first on Med Ed 101.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
I received a question the other day about the use of bisphosphonates in patients who may have a limited life expectancy but have osteoporosis or are at risk for osteoporosis. It is a very good question and that determination is going to be made on a case by case basis. Arguably the biggest challenge with […]. The post Starting Bisphosphonates in Patients With Limited Life Expectancy appeared first on Med Ed 101.
40
40
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content